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Summary.-During studies of the ability of antilymphocyte serum (ALS) to suppress
the immune mechanism of mice and thereby allow HeLa cells to grow into a large
tumour in the mice, it was observed that many tumours continued to grow even
after the ALS treatment had been stopped and full immunological competence of the
mice had returned. The HeLa cells of such tumours appeared to be unchanged in
their ability to induce further tumours in ALS treated mice to which they were
transferred and, furthermore, the mice which were carrying such tumours in the
presence of immunological competence were able to reject additional injections of
HeLa cells or other human tumour cells. The four possible explanations for this
phenomenon, (i) depression of cellular response; (ii) local reaction at the graft site;
(iii) the presence of a blocking factor; and (iv) the elevation of the humoral response,
have been investigated.
IN 1967 and 1968, Philips and Gazet
shQwed that human tumour xenografts
grow in mice which had been treated with
aritilymphocyte serum (ALS). These
results were confirmed by Stanbridge and
Perkins (1969) using HeLa cells. In both
of these reports, it was shown that the
period of active growth of the tumour
was short-lived and was eventually
followed by regression when the ALS
treatment was terminated.
However, in carrying out similar work,
we have observed that the growth of
tumour cells was maintained for very long
periods in a significant number of mice, in
spite of the fact that ALS treatment had
been terminated. This was surprising,
since it has been reported (Medawar, 1969)
that mice recover full immunological
competence some 50 days after the com-
pletion of ALS treatment. If a return
had been made to full immunological
competence, identical to that existing in
untreated mice, then the tumours should
have regressed. In the untreated mouse,
for example, tumour cells do not grow
much beyond 4 days aftertheirinoculation
and total rejection occurs by the tenth
day. In the present investigations we
report tumour survival for many months
in mice treated initially with ALS, and
have studied the immune state of such
tumour bearing mice.
MATERIALS AND METHODS
Antilymphocyte serum was prepared by
the method of Levey and; Medawar (1966a).
Mice received 0-25 ml of ALS on the day
beforegivingHeLa cells (Day -1), ontheday
ofgivingthecells (Day0), andsubsequentlyon
Days 1, 3, 9 and 16 aftergiving the cells. All
mice were inoculated with 2 x 105 HeLa
cells in a 0'2 ml inoculum, by the sub-
cutaneous route, at a ventro lateral site in
the region of the hip joint. Inoculation of
the cells at this site alleviates the problem of
pressure necrosis, which is seen when the cells
are inoculated in a ventral position of the
mouse.
Smears were made of peripheral mouse
blood and were examined microscopically for
the presence of circulating lymphocytes.
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with fluorescein-isothiocyanate, and was then
used to demonstrate the presence of thymus-
dependent (T) lymphocytes in peripheral
blood by direct immunofluorescence.
The cytotoxic antibody levels in sera were
measured in vitro using a trypan blue dye
exclusion test, as follows: confluent HeLa
cells less than one week old were trypsinized
and then placed in a 5 cm diameter Falcon
plastic petri dish which contained two sterile
glass cover slips. The petri dish and con-
tents were incubated in CO2 at 37°C for 4
hours, during which time the cells settled on
the cover slips. Before use each cover slip
was washed in warmed normal saline and the
excess saline was removed. To the cells on
each coverslip 2A of the serum under test
was added together with 2A of absorbed
guinea-pig complement (Cohen and Schle-
singer, 1970) and this followed by incubation
in a moist atmosphere for 30 min at
37°C. It was then washed again and dried.
Just sufficient 0.2% trypan blue was added to
cover the cells and left to stain for 2 min.
The trypan blue was poured offand the cover
slip washed in normal saline, dried and
mounted on a clean slide in normal saline.
The percentage mortality of the HeLa cells
on the cover slip was determined by direct
count of the percentage of the cells which
wete stained.
The sera were examined also for blocking
factor after the removal of cytotoxic activity
present by absorption in vitro with HeLa
cells. The absorbed sera, 0-25 ml, was then
injected subcutaneously into normal mice
before the inoculation of 2 x 105 HeLa cells
in a 0-2 ml inoculum. Control mice received
0-25 ml of normal mouse sera, also treated in
vitro with HeLa cells.
The mice were young female adults ofthe
National Institute of Medical Research CBA
strain, and the HeLa cells were obtained from
the Central Public Health Laboratory. On
each occasion, the HeLa cells were cultured
in vitro for 4-7 days before inoculation into
the mice.
RESULTS
In all groups of mice treated with the
same batch of ALS, HeLa cells produced
tumours which grew in all the mice up to
Day 33, in spite of the fact that the
administration of ALS was terminated on
Day 16. From Day 33 to Day 60 one-
26
third ofthe mice rejected the tumours and
beyond Day 60 the survival of tumours
was maintained in the remaining two-
thirds. The comparison of the survival
oftumours between treated and untreated
mice is shown in Fig. 1.
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FIG. 1.-Survival of HeLa tumours in ALS
treated mice (A) and untreated mice (A).
In the group of mice not treated with
ALS a small tumour nodule was palpable
up to Day 4 but from this time to Day 10
there was a gradual regression of tumours
such that at Day 10 no tumours could be
detected.
The reasons for survival of tumours in
treated mice
Lymphocytes were found to be present
in all the smears of peripheral mouse
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blood examined. During the administra-
tion of ALS, there was a severe transitory
depletion of the lymphocyte count but
from Day 16, following the final injection
of ALS, there was a gradual return to
normality.
Since it is believed that the reaction of
specifically sensitized T lymphocytes re-
sults in the rejection of a tumour, their
presence would help to explain why
regression occurred in one group of ALS
treated mice, and their absence account
for long-term survival in the other.
However, T cells were found to be present
in both groups of mice whether tumours
had regressed or become established as
long-term HeLa tumours. A quantitative
analysis, however, was not made during
these immonofluorescence studies.
Further tests were made for immuno-
logical competence by the injection of a
different human cell line into the mice
already bearing long-term HeLa tumours.
For this purpose Hep 2 cells were used
and it was shown that all mice bearing
long-term HeLa tumours, when inoculated
with 3.5 X 106 Rep 2 cells subcutaneously
rejected the Hep 2 cells by Day 4. In the
control mice given ALS and Hep 2 cells
alone, there was no sign of rejection until
after Day 11, but from Day 11 to Day 17
there was a 60% rejection rate. Mice
bearing long-term tumours were then
injected subcutaneously with 2.5 x 105
HeLa cells and all failed to develop
additional HeLa cell tumours.
Tests on HeLa cells producing tumours in
ALS treated mice
An attempt was made to determine
whether the HeLa cells, growing as long-
term tumours, had undergone a change in
surface antigenicity. Some of the tu-
mour-bearing mice were killed and the
tumours excised. The cells from such
tumours taken 103 days after the inocu-
lation of the HeLa cells were cut into
approximately 2 mm squares and im-
planted subcutaneously into ALS treated
and untreated mice. It was found that
in 670% of the ALS treated mice the im-
plant developed into a HeLa tumour; in
the untreated mice, however, implantatiorL
with similar tumour material resulted in
a palpable nodule on Day 2 in 57%O of the
mice, on Day 8 in 44 o, on Day 11 in only
6% and total rejection occurred in all
mice by Day 13. Therefore the HeLa
cells taken from mice previously treated
with ALS, and which had actively growing
tumours, did not differ in a significant way
from those HeLa cells taken directly from
an in vitro culture used in the initial
inoculation oftreated and untreated mice.
Histological examination of the tumour
A histological examination was made
of tumours surviving for a long time in
mice that were treated initially with ALS.
The sections showed the absence of a
lymphocytic infiltration and the presence
of active mitosis. The centres of large
tumours (that is those in excess of 2 cm)
appeared to be filled with necrotic tissue.
Although the tumours received a blood
supply, by means of a pedicle from the
mouse abdominal wall, it is suggested that
this was inadequate to satisfy the require-
ments of such a fast growing mass of cells.
In addition to these histological ex-
aminations, a comprehensive macroscopic
and microscopic examination was made of
the liver, kidney, supra-renals, lungs,
spinal cord, brain, ovaries and the lymph
nodes, but none showed signs of HeLa
tumour metastases.
Serological examinations
The sera from mice treated with ALS
as well as from untreated mice were
examined for in vitro cytotoxic activity,
using the trypan blue dye exclusion test.
The results of this examination are
shown in Fig. 2. It is clear that the
cytotoxic activity was highest, and more
sustained, in ALS treated mice in which
regression of tumours had occurred. In
the mice treated with ALS in which
tumours survived for a long time the
cytotoxic activity was still high, but the
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FIG. 2.-In vitro cytotoxic titres in ALS treated
mice with long-term tumours (A), ALS treated
mice with regressed tumours (A), Control mice
with regressed tumours (DC1).
peak was not sustained for such a long
period. In the untreated control mice in
which tumours regressed rapidly the
cytotoxic activity was lower and short
lived.
The sera from these mice were ex-
amined also for the presence of blocking
factors, i.e. an antibody that binds to the
target HeLa cells, or a complex of antigen
and antibody that could bind to target or
effector cells, thus delaying or preventing
the rejection ofthe HeLa tumour. It was
shown by the in vivo method used that
such a blocking mechanism appeared to
be present. Although there was no direct
relationship between in vitro cytotoxic
activity and in vivo blocking potential
using the absorbed sera, it was found that
sera with high in vitro cytotoxic titres had
the greatest blocking potential. How-
ever, it was not possible to extend HeLa
tumour survival much beyond Day 14 in
normal mice treated with absorbed sera
before the inoculation of HeLa cells.
Histological examination of the nodule so
derived showed it to be a HeLa tumour
and not an inflammatory response to the
inoculation of foreign cells. Normal sera
treated with HeLa cells in vitro had no
blocking effect. These observations are
currently being investigated further.
DISCUSSION
These studies have shown that mice
treated with ALS before the inoculation
of HeLa cells have a long-term tumour
survival rate of 67%. It is generally
believed that ALS selectively depresses
the cellular immune response (Levey and
Medawar, 1966b) and that allograft
rejection is controlled by this cellular
response (Mitchison, 1955). Although our
systqm is not an allograft system, it is
reasonable to correlate the graft survivals
with depression ofthis response, which we
observed as a result of ALS treatment as
well. In untreated mice, tumours will
not grow much beyond Day 4.
Medawar (1969) has shown that ALS
treated mice do not recover full immuno-
logical competence until some 50 days
after the end of ALS treatment. In our
investigations this would be at about Day
66, ALS treatment having ended on Day
16. However, we have found that the
highest rejection rate occurs between Day
33 and Day 60. This observation would
appear to contradict Medawar's findings,
particularly as graft rejection is controlled
by the cellular immune response, unless
there is an additional process controlling
xenograft rejection. We have found that
the high rejection rate of HeLa tumours
between Day 33 and Day 60 occurs con-
currently with a considerable elevation of
the humoral response. Although it may
be argued that in vitro cytotoxic activity
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is not necessarily an indication of the in
vivo state of the immune mechanism, the
presence of a high in vitro cytotoxic
activity during this period of maximal
tumour regression seems to be significant,
and may be a controlling factor in this
system. Raised humoral antibody levels
have been reported before in response to
tumour xenografts (Beverly and Simpson,
1970).
Our investigations into the presence of
a blocking antibody have shown that sera
with high cytotoxic titres, measured in
vitro, appear to have in vivo blocking
activity. Although we have only suc-
ceeded in increasing the HeLa cell turmour
mean survival rate from 4 to 14 days, when
absorbed sera are passively passaged into
normal mice before the inoculation of
HeLa cells, we feel that the constancy of
the observation must be due to some
factor in the sera which is not present in
normal sera. The detection of a blocking
antibody reinforces the hypothesis that
enhancement may be an additional factor
contributing to long-term tumour survival,
though in view ofthis limited extensiln of
graft growth using passive serum transfer,
its significance is equivocal. Enhance-
ment has been demonstrated many times
for allogeneic tumours (Takasugi and
Hildemann, 1969a, b) and recently for syn-
geneic tumours (Hellstrom and Hellstrom,
1970).
The observations reported here do not
support the hypothesis that immuno-
logical tolerance is a satisfactory explana-
tion for this phenomenon. They fail also
to support the hypothesis that long-term
survival of tumours is a function of a
change in surface antigenicity during
growth in vivo. Passaged tumours were
rejected in untreated mice though the
mean time for rejection was increased.
This was probably due to the greater size
of the passaged HeLa cell implant over
and above that given by an initial inocu-
lation of cell suspension.
The tumours that survive are well
localized at the site of inoculation, have a
good blood supply and are coated with a
hypofibrous layer. There is a complete
absence of macroscopic and microscopic
metastases and the host mice have been
shown to reject another human tumori-
genic cell line and, furthermore, they
rapidly destroy additional inoculations of
the original HeLa cells even though they
continue to maintain the original HeLa
cell tumour. This phenomenon of con-
comitant immunity has been observed by
many investigators in the field of tumour
transplantation (Ehrlich, 1906; 1908;
Gershon, Carter and Kondo Kazunari,
1967; Carter, 1970), and may be explained
by the fact that tumour survival is a result
of a local reaction at the graft site.
Wre feel that long-term tumour survival
is not yet fully understood and there may
be more than one controlling factor
involved. In our investigations we have
referred to four possibilities: depression of
the cellular response, a local reaction at
the graft site, the effect of blocking factor
and the elevation ofthe humoral response.
It is suggested that only when these are
acting in the same direction tumour
survival occurs. It is not surprising
therefore that there is a 33%0 failure rate.
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